Your browser doesn't support javascript.
Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension
Guang Yang; Zihu Tan; Ling Zhou; Min Yang; Lang Peng; Jinjin Liu; Jingling Cai; Ru Yang; Junyan Han; Yafei Huang; Shaobin He.
  • Guang Yang; Department of Geriatrics, Hubei Provincial Hospital of Traditional Chinese Medicine; Hubei Provincial Academy of Traditional Chinese Medicine.
  • Zihu Tan; Department of Geriatrics, Hubei Provincial Hospital of Traditional Chinese Medicine; Hubei Provincial Academy of Traditional Chinese Medicine
  • Ling Zhou; Zhongnan Hospital of Wuhan University
  • Min Yang; Department of Preventive Medicine, School of Basic Medicine, Hubei University of Chinese Medicine
  • Lang Peng; Department of Geriatrics, Hubei Provincial Hospital of Traditional Chinese Medicine; Hubei Provincial Academy of Traditional Chinese Medicine
  • Jinjin Liu; Department of Geriatrics, Hubei Provincial Hospital of Traditional Chinese Medicine; Hubei Provincial Academy of Traditional Chinese Medicine
  • Jingling Cai; Department of Geriatrics, Hubei Provincial Hospital of Traditional Chinese Medicine; Hubei Provincial Academy of Traditional Chinese Medicine
  • Ru Yang; Wuhan Blood Center
  • Junyan Han; Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology
  • Yafei Huang; Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology
  • Shaobin He; Department of Geriatrics, Hubei Provincial Hospital of Traditional Chinese Medicine; Hubei Provincial Academy of Traditional Chinese Medicine
Preprint in English | medRxiv | ID: ppmedrxiv-20038935
ABSTRACT
With the capability of inducing elevated expression of ACE2, the cellular receptor for SARS-CoV-2, angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (ARBs/ACEIs) treatment may have a controversial role in both facilitating virus infection and reducing pathogenic inflammation. We aimed to evaluate the correlation of ARBs/ACEIs usage with the pathogenesis of COVID-19 in a retrospective, single-center study. 126 COVID-19 patients with preexisting hypertension at Hubei Provincial Hospital of Traditional Chinese Medicine (HPHTCM) in Wuhan from January 5 to February 22, 2020 were retrospectively allocated to ARBs/ACEIs group (n=43) and non-ARBs/ACEIs group (n=83) according to their antihypertensive medication. 125 age- and sex-matched COVID-19 patients without hypertension were randomly selected as non-hypertension controls. In addition, the medication history of 1942 hypertension patients that were admitted to HPHTCM from November 1 to December 31, 2019 before COVID-19 outbreak were also reviewed for external comparison. Epidemiological, demographic, clinical and laboratory data were collected, analyzed and compared between these groups. The frequency of ARBs/ACEIs usage in hypertension patients with or without COVID-19 were comparable. Among COVID-19 patients with hypertension, those received either ARBs/ACEIs or non-ARBs/ACEIs had comparable blood pressure. However, ARBs/ACEIs group had significantly lower concentrations of CRP (p=0.049) and procalcitonin (PCT, p=0.008). Furthermore, much lower proportion of critical patients (9.3% vs 22.9%; p=0.061), and a lower death rate (4.7% vs 13.3%; p=0.216) were observed in ARBs/ACEIs group than non-ARBs/ACEIs group, although these differences failed to reach statistical significance. Our findings thus support the use of ARBs/ACEIs in COVID-19 patients with preexisting hypertension.
Full text: Available Collection: Preprints Database: medRxiv Type of study: Randomized controlled trials / Risk factors Topics: Traditional medicine Language: English Year: 2020 Document Type: Preprint

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Collection: Preprints Database: medRxiv Type of study: Randomized controlled trials / Risk factors Topics: Traditional medicine Language: English Year: 2020 Document Type: Preprint